Back to Search
Start Over
CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications.
- Source :
-
Human Gene Therapy . May2018, Vol. 29 Issue 5, p559-568. 10p. - Publication Year :
- 2018
-
Abstract
- The adoptive transfer of chimeric antigen receptor (CAR)-modified T cells is attracting growing interest for the treatment of malignant diseases. Early trials with anti-CD19 CAR T cells have achieved spectacular remissions in B-cell leukemia and lymphoma, so far refractory, very recently resulting in the Food and Drug Administration approval of CD19 CAR T cells for therapy. With further applications and increasing numbers of patients, the reproducible manufacture of high-quality clinical-grade CAR T cells is becoming an ever greater challenge. New processing techniques, quality-control mechanisms, and logistic developments are required to meet both medical needs and regulatory restrictions. This paper summarizes the state-of-the-art in manufacturing CAR T cells and the current challenges that need to be overcome to implement this type of cell therapy in the treatment of a variety of malignant diseases and in a greater number of patients. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 10430342
- Volume :
- 29
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Human Gene Therapy
- Publication Type :
- Academic Journal
- Accession number :
- 129382581
- Full Text :
- https://doi.org/10.1089/hum.2017.254